|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.51 EUR | +1.85% |
|
+6.93% | -11.40% |
| Sep. 05 | Bayer gains significantly - focus on US glyphosate dispute | DP |
| Sep. 05 | Bayer: new data for menopause treatment | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
| Capitalization | 28.47B 31.66B | P/E ratio 2024 * |
12.2x | P/E ratio 2025 * | 9.75x |
|---|---|---|---|---|---|
| Enterprise value | 62.35B 69.33B | EV / Sales 2024 * |
1.33x | EV / Sales 2025 * | 1.24x |
| Free-Float |
100% | Yield 2024 * |
0.38% | Yield 2025 * | 0.38% |
More valuation ratios
* Estimated data
More news
Last Transcript: Bayer AG
More press releases
More news
| 1 day | +1.98% | ||
| 1 week | +4.19% | ||
| Current month | +3.98% | ||
| 1 month | +7.53% | ||
| 3 months | +1.33% | ||
| 6 months | +11.64% | ||
| Current year | -13.84% |
1 week
27.38
29.49
1 month
25.3429.74
Current year
24.9636.09
1 year
24.9651.32
3 years
24.9667.99
5 years
24.9678.34
10 years
24.96146.45
| Director | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 58 | 23-03-31 |
| Director of Finance/CFO | 55 | 18-04-25 | |
Christian Rommel
CTO | Chief Tech/Sci/R&D Officer | 57 | 21-01-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Achleitner
BRD | Director/Board Member | 68 | 02-03-31 |
André van Broich
BRD | Director/Board Member | 54 | 12-03-31 |
| Director/Board Member | 64 | 22-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.77% | 70 M€ | -.--% | ||
| 5.71% | 2 M€ | +13.56% | - | |
| 4.28% | 962 M€ | -.--% | - | |
| 4.10% | 0 M€ | 0.00% | - | |
| 4.10% | 0 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +1.60% | +4.19% | -42.79% | -38.97% | 31.56B | ||
| -3.55% | -2.92% | +63.52% | +251.69% | 822B | ||
| -1.25% | -4.01% | +33.76% | +181.19% | 583B | ||
| -1.42% | +0.46% | +2.68% | -5.74% | 397B | ||
| -2.11% | -1.19% | +32.01% | +72.78% | 341B | ||
| +2.41% | +0.96% | +10.31% | +53.49% | 301B | ||
| +0.17% | -5.53% | +16.80% | +47.37% | 256B | ||
| -0.67% | -3.22% | +8.78% | -24.28% | 262B | ||
| -1.06% | -2.95% | +12.67% | +18.64% | 236B | ||
| -1.90% | -2.01% | +27.70% | +43.29% | 174B | ||
| Average | -0.05% | -1.62% | +16.54% | +59.95% | 340.35B | |
| Weighted average by Cap. | -0.22% | -2.31% | +29.39% | +107.99% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 47.01B 52.28B | 47.67B 53.02B |
| Net income | 2.28B 2.53B | 3.02B 3.36B |
| Net Debt | 33.88B 37.68B | 30.44B 33.85B |
More financial data
* Estimated data
Employees
96,567
Sector
Pharmaceuticals
Calendar
2024-11-05
- Q3 2024 Earnings Release
Related indices
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-09-06 | 29.64 € | +2.28% | 445,477 |
| 24-09-05 | 28.98 € | +3.89% | 4,764,490 |
| 24-09-04 | 27.89 € | +0.29% | 1,976,412 |
| 24-09-03 | 27.81 € | -0.78% | 2,732,336 |
| 24-09-02 | 28.03 € | +0.59% | 1,835,813 |
Delayed Quote Xetra, September 05, 2024 at 11:44 am EDT
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
28.98EUR
Average target price
35.41EUR
Spread / Average Target
+22.21%
- Stock Market
- Equities
- BAYN Stock
